GeneDx Holdings

GeneDx Holdings Receivables

The Accounts Receivable of GeneDx Holdings (WGS) as of Oct 29, 2026 is 37.43 M USD. In the previous year, Accounts Receivable was 32.37 M USD — a change of 15.62% (higher).

Receivables

37.43 MUSD

YoY

15.62%

Last updated:

Accounts Receivable of GeneDx Holdings is 2024 37.43 M USD. Accounts Receivable of GeneDx Holdings was 2023 32.37 M USD. It decreases by 15.62% higher compared to the previous year.

The GeneDx Holdings Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2019
21.40 M USD
Jan 1, 2020
32.00 M USD
Jan 1, 2021
26.50 M USD
Jan 1, 2022
42.60 M USD
Jan 1, 2023
32.37 M USD
Jan 1, 2024
37.43 M USD
The GeneDx Holdings Receivables history
YEARReceivablesYoY
37.43 MUSD+15.62%
32.37 MUSD-24.01%
42.60 MUSD+60.75%
26.50 MUSD-17.19%
32.00 MUSD+49.53%
21.40 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneDx Holdings Stock analysis

What does GeneDx Holdings do? GeneDx Holdings Corp. generates revenue through its GeneDx and Legacy Sema4 segments. The GeneDx segment offers pediatric and rare disease diagnostics, primarily utilizing whole exome and genome sequencing, along with data and information services. It provides genetic diagnostic tests, screening solutions, and information to clinicians and patients. The Legacy Sema4 segment delivers reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. Both segments target healthcare providers and institutions seeking personalized health insights for diagnosis, treatment planning, and drug discovery. The company’s products include genetic diagnostic tests, screening solutions, and information services under the GeneDx brand, while Legacy Sema4 focuses on reproductive health, women’s health, and oncology diagnostics. These services are sold to healthcare providers and institutions that require actionable health intelligence to inform clinical decisions and improve patient outcomes. The segments serve distinct medical specialties, with GeneDx emphasizing rare diseases and pediatric care, and Legacy Sema4 covering reproductive health and cancer diagnostics. Revenue is derived from diagnostic testing services provided through both segments. The GeneDx segment’s core offerings are whole exome and genome sequencing for rare and pediatric conditions, while Legacy Sema4 specializes in reproductive, women’s health, and somatic oncology testing. These services are delivered to healthcare systems and providers who integrate genetic data into patient care pathways for better diagnosis and treatment strategies. GeneDx Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneDx Holdings stock

Accounts Receivable of GeneDx Holdings is 37.43 M USD in 2024.

Accounts Receivable of GeneDx Holdings changed from 32.37 M USD to 37.43 M USD, representing a 15.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable GeneDx Holdings since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's GeneDx Holdings historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneDx Holdings

All Key Metrics — GeneDx Holdings